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Abstract
Background: A prospective study was performed to investigate the prevalence of colonization among ICU
patients and to examine whether asymptomatic carriers were the source of subsequent C. difficile infection
(CDI) and acquisition of toxigenic C. difficile.
Methods: Rectal swabs were collected from adult patients on admission to and at discharge from a 50-bed medical
ICU of a major referral hospital in western China, from August to November 2014. Stools were collected from patients
who developed ICU-onset diarrhea. Both swabs and stools were screened for tcdB (toxin B gene) by PCR. Samples
positive to tcdB were cultured for C. difficile and isolates recovered were screened for tcdB and the binary toxin genes
by PCR. Strain typing was performed using multilocus sequence typing and isolates belonging to the same sequence
type (ST) were further typed using multiple-locus variable number tandem repeat analysis (MLVA).
Results: During the 4-month period, rectal swabs were collected from 360 (90.9 %) out of 396 patients who were
admitted to the ICU. Among the 360 patients, 314 had stayed in the ICU more than 3 days, of which 213 (73.6 %)
had a rectal swab collected within the 3 days prior to discharge from ICU. The prevalence of toxigenic C. difficile
colonization was 1.7 % (6 cases) and 4.3 % (10 cases) on admission and discharge, respectively. Only four (1.1 %) out
of 360 patients had CDI, corresponding to 10.7 cases per 10,000 ICU days. None of the four cases had toxigenic C.
difficile either on admission or at discharge. Toxigenic C. difficile isolates were recovered from all swabs and
stool samples positive for tcdB by PCR and belonged to 7 STs (ST2, 3, 6, 37, 54, 103 and 129). None of the
isolates belonging to the same ST had identical MLVA patterns. Binary toxin genes were detected in one
ST103 isolate that caused colonization.
Conclusion: The prevalence of colonization with toxigenic C. difficile among patients on admission to ICU was
low in our setting. ICU-acquired toxigenic C. difficile were not linked to those detected on admission. Active
screening for toxigenic C. difficile may not be a resource-efficient measure in settings with a low prevalence
of colonization.
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Background
Toxigenic Clostridium difficile has been well recognized as
a major pathogen causing healthcare-associated infections
in western countries [1]. In healthcare settings, C. difficile
can be transmitted via contact with patients or their
environment directly or indirectly. Contact precautions are
therefore required when C. difficile infection (CDI) is sus-
pected [2, 3]. Some patients can be colonized with toxigenic
C. difficile but without manifestations of CDI. These
asymptomatic carriers may serve as an important reservoir
of toxigenic C. difficile [4] and appear to have significant
higher risks of subsequent CDI [5]. Active screening pa-
tients for toxigenic C. difficile may therefore have two bene-
fits. One is to identify the source of this pathogen for
subsequent control measures, such as contact precautions
for carriers, and another is to identify the population at
high risk of CDI. However, active screening is resource-
intensive and requires corresponding laboratory capacity,
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which may be problematic in developing countries like
China. In settings with a high prevalence of colonization
with toxigenic C. difficile and where nosocomial transmis-
sion is frequently linked to asymptomatic carriers, it may
be justified to include active screening in the prevention
and control of CDI. There are a few studies on the preva-
lence of colonization for inpatients and residents in long-
term care facilities or nursing homes [5, 6]. However,
colonization with toxigenic C. difficile among ICU patients
remains largely uninvestigated. In addition, little is known
about the carriage and transmission of toxigenic C. difficile
in China. We therefore performed a prospective study to
investigate the prevalence of colonization with toxigenic C.
difficile among patients in a large ICU of a major teaching
hospital in China and to examine whether the toxigenic C.
difficile isolates acquired during the ICU stay were linked
to asymptomatic carriers who were colonized on admission
to the unit.
Methods
Patient enrollment and sample collection
This prospective study was conducted among adult pa-
tients (age ≥16) at a 50-bed medical ICU ward in West
China Hospital, Sichuan University, the major referral
medical center in western China, during a 4-month
period from August to November 2014. This study was
conducted in accordance with the amended Declaration
of Helsinki and was approved, under a waiver of con-
sent, by the Ethics Committee of West China Hospital.
Stool samples and rectal swabs were taken as part of
routine care as collecting stool specimens or rectal
swabs for screening multidrug resistant organisms such
as extended-spectrum β-lactamase-producing Entero-
bacteriaceae and vancomycin-resistant enterococci has
been a routine practice in the ICU.
Rectal swabs were collected from patients within 2 days
of admission to the ICU and also within the 3 days prior
to ICU discharge for those patients with a length of stay
of 3 days or more. Swabs were transferred to the labora-
tory in transport media. Stool samples were also col-
lected from patients who developed ICU-onset diarrhea
with naturally-passed faeces that were defined as un-
formed at least 3 times a day.
The presence of toxigenic C. difficile in a rectal swab
or stool sample was detected by PCR for the toxin B-
encoding gene tcdB of C. difficile (see below). A car-
rier was defined as a patient without diarrhea whose
rectal swab was positive for toxigenic C. difficile. CDI
here was defined as diarrhea plus the presence of toxi-
genic C. difficile in stool, in the absence of other rea-
sonable causes of diarrhea. Screening results were not
shared with ICU clinicians and infection control
nurses and no contact precautions were taken for car-
riers of toxigenic C. difficile.
Screening, culture and PCR confirmation
Swabs and stool samples were processed immediately
after arrival at the laboratory. Total DNA was prepared
from swabs and stool using the Stool DNA Kit (OMEGA,
Norcross, GA) and was screened for the species-specific
gene tpi (encoding triose phosphate isomerase of C. diffi-
cile) and tcdB of C. difficile by PCR as described previ-
ously [7, 8].
Samples positive for both tpi and tcdB were cultured
anaerobically. Briefly, samples were treated with an equal
volume of 95 % ethanol before streaking onto cefoxitin
cycloserine fructose agar (CCFA; OXOID, Basingstoke,
UK) plates complemented with the CDMN supplement
(OXOID) and 5 % sheep blood. Plates were incubated in
anaerobic jars at 37 °C for 72 h. All isolates recovered
were checked by morphological examination and aeroto-
lerant experiments.
Genomic DNA was prepared from each isolate using
the QIAamp DNA mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions for Gram-
positive organisms. Isolates were confirmed as toxigenic
C. difficile using PCR for tpi and tcdB [7, 8]. Toxigenic C.
difficile isolates were also screened for the enterotoxin-
encoding gene tcdA and binary toxin genes cdtA and
cdtB using multiplex PCR [7, 8]. Isolates recovered
were considered ICU-acquired if the host patient had
no toxigenic C. difficile in the swab collected within
2 days of admission.
Strain typing
Strain typing of toxigenic isolates was performed using
multilocus sequence typing (MLST) as described previ-
ously [9]. Sequence types (STs) of C. difficile were also
clustered into clades by phylogenetic analysis using the
concatenated sequences of the seven loci of MLST [9].
For isolates belonging to the same ST, multiple-locus
variable-number tandem repeat analysis (MLVA) was
performed to further determine the relatedness of these
isolates as described before [4]. The 6-loci MLVA
scheme developed by Marsh J et al. [4, 10] was used and
the exact size of amplicons was determined by capillary
electrophoresis using an ABI 3730xl (Applied Biosys-
tems, Carlsbad, CA).
Statistical analysis
Statistical analysis was performed using SPSS version
18.0 (SPSS Inc., Chicago, IL). Proportions were com-
pared using a Chi-Squared test and a P value <0.05 was
considered statistically significant.
Results
During the 4-month period, a total of 396 adult patients
were admitted to the ICU, among which rectal swabs
were collected from 360 (90.9 %) patients within 2 days
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of admission to ICU (Fig. 1). Among the 360 patients,
314 had stayed in the ICU for at least 3 days, with rectal
swabs collected from 231 (73.6 %, 231/314) patients
within the 3 days prior to ICU discharge (Fig. 1). Only 6
(1.7 %, 6/360) patients had toxigenic C. difficile on ad-
mission, while 10 (4.3 %, 10/231) had it at discharge. As
none developed diarrhea during their hospitalization in
ICU, all 16 patients positive for toxigenic C. difficile (ei-
ther on admission or at discharge) were classified as
carriers. Of the 6 carriers of toxigenic C. difficile on
admission, 4 had a rectal swab collected within 3 days of
discharge but toxigenic C. difficile was not detected. For
all 10 carriers of toxigenic C. difficile at discharge, swabs
collected on admission were negative, suggesting that
they acquired toxigenic C. difficile during their ICU stay.
The prevalence of colonization with toxigenic C. difficile
on admission appeared to be higher in patients who
were 65 or older (3.3 %, 4/122) than that in those who
were younger (0.8 %, 2/238) but this difference was not
statistically significant (P = 0.2). Most (8/10) of patients
acquired toxigenic C. difficile during their ICU stay were
also 65 or older and had a higher rate of acquisition of
toxigenic C. difficile (9.9 %, 8/81) than those who were
younger (1.3 %, 2/150; P < 0.05).
Toxigenic C. difficile isolates were recovered from all
of the 16 carriers detected by PCR. Among these 16
toxigenic isolates, 10 were positive for tcdA and tcdB
(A + B+) and 6 were positive for tcdB only (A-B+). In
addition, binary toxin genes were detected in one iso-
late, which was collected at discharge and was A + B+.
The 6 isolates recovered from swabs collected on ad-
mission belonged to four STs, i.e. ST2 (n = 1), ST3 (n =
2), ST6 (n = 1) and ST54 (n = 2) (Fig. 1 and Table 1). In
contrast, most (6 of 10) isolates recovered from swabs
collected at discharge belonged to ST37, which was not
detected on admission. The remaining four isolates re-
covered from swabs collected at discharge belonged to
ST2 (n = 1), ST54 (n = 2) and ST103 (n = 1) (Fig. 1 and
Table 1). The isolate carrying binary toxin genes
belonged to ST103.
During their ICU stay, 54 (15.0 %) out of 360 patients
developed diarrhea, of which four cases (1.1 %, 4/360;
their ages ranged from 35 to 73) were CDI. The length
of ICU stay was 3,744 ICU days for the 360 patients and
CDI incidence was 10.7 cases per 10,000 ICU days.
None of the four cases were positive for toxigenic C.
difficile either on admission or at discharge. Toxigenic
C. difficile was cultured from all four patients and
belonged to ST3 (n = 1), ST37 (n = 2) or ST129 (n = 1)
(Fig. 1 and Table 1).
In total, 20 toxigenic C. difficile isolates were recov-
ered from either swabs or stool samples. The 20 isolates
belonged to 7 STs (ST2, ST3, ST6, ST37, ST54, ST103
and ST129; Table 1). Toxigenic C. difficile could be clus-
tered into four clades based on STs [9]. Among the 7
STs identified in this study, ST5 belongs to clade 3 and
ST37 belongs to clade 4, while the remaining STs were
of clade 1 (Table 1). As there were multiple isolates of
ST2 (n = 2), ST3 (n = 2), ST37 (n = 8) and ST54 (n = 4),
those belonging to the same ST were further typed using
MLVA. However, none of these isolates had identical
MLVA patterns (Fig. 1 and Table 1).
Discussion
Previous studies revealed that the prevalence of
colonization with toxigenic C. difficile in adult hospital-
ized patients varied from 4.4 % to 23.2 % [6] with the
pooled rate being 8.1 % [5]. However, very few studies
investigated the colonization of toxigenic C. difficile
among ICU patients. In a study at Johns Hopkins Hos-
pital, 3.1 % of patients were colonized with toxigenic C.
difficile on admission to ICU. This suggests that the
colonization rate of toxigenic C. difficile in ICU patients
may be lower than those described for the general
Fig. 1 Summary of results in this study
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population due to as yet unknown reasons [11]. We can-
not rule out that the low prevalence of colonization with
toxigenic C. difficile on admission to ICU may be due to
the use of a rectal swab rather than stool. However, prior
studies have demonstrated that rectal swabs and stool
cultures were equivalent for detection of C. difficile in
stool of CDI patients [12, 13]. Nonetheless, the low
prevalence (1.7 %) of colonization on admission to ICU
in our study was even lower than the 3.1 % in study
from Johns Hopkins Hospital, which also used rectal
swabs for screening. The differences in colonization rate
among studies remain unclear but may reflect the popu-
lation risk of colonization with toxigenic C. difficile as
previous studies have demonstrated that the prevalence
of colonization with toxigenic C. difficile varies signifi-
cantly by geographic location [6]. Although the preva-
lence of toxigenic C. difficile in China remains still
largely unknown, it is possible that the prevalence of
colonization with toxigenic C. difficile in China is truly
lower than that in western countries. This may not be a
surprise as there are significant differences in food and
drinking habits between China and western countries.
However, large-scale multi-center studies are required to
fully characterize the prevalence of toxigenic C. difficile
in China.
A systematic review and meta analysis found that pa-
tients colonized with toxigenic C. difficile on hospital
admission were 6 times more likely to develop CDIs
compared with noncolonized patients [5]. In the previ-
ous study on ICU patients, colonization with toxigenic
C. difficile on admission and colonization during ICU
stay have also been identified as an independent risk
factors for subsequent CDI with relative risks being 8.62
and 10.93, respectively [11]. However, it has also been
thought that colonization with C. difficile could be pro-
tected from subsequent CDI [14]. In this study, none of
the six patients colonized with toxigenic C. difficile on
admission and none of the ten patients colonized at
discharge developed diarrhea during their ICU stay. Pa-
tients who were 65 years of age or older had a much
higher risk of developing CDI than younger patients
[15]. Our study found that patients who were 65 or older
were also more likely to acquire toxigenic C. difficile and
become asymptomatic carriers during their ICU stay.
Table 1 Characteristics of patients with toxigenic C. difficile
Patient ICU stay, d Diseases Collection date ST Cladea MLVA profileb
Isolates detected on admission
1 13 Cholangitis, bacteremia November 2 1/HA1 316/171/264/280/280/371
2 19 Stroke September 3 1/HA1 259/187/329/365/365/117
3 7 Systemic EB virus positive T lymphocyte
proliferative disease, pneumonia
September 3 1/HA1 425/195/243/336/336/455
4 27 Pneumonia, Guillain-Barré syndrome November 6 1/HA1 ND
5 6 Septic shock, colon cancer August 54 1/HA1 322/171/286/365/365/117
6 4 Gastric cancer, pneumonia September 54 1/HA1 322/171/286/344/344/223
Isolates detected on discharge
7 12 Pneumonia, uremia October 2 1/HA1 259/164/263/344/344/488
8 12 Embedded abdominal wall hernia August 37 4/A-B+ 129/336/209/314/314/420
9 6 Septic shock, ovian cancer October 37 4/A-B+ 129/344/209/294/293/438
10 10 Brain glioma October 37 4/A-B+ 129/336/209/307/307/421
11 17 Liver cirrhosis November 37 4/A-B+ 129/367/209/300/300/438
12 32 Pancreatitis November 37 4/A-B+ 129/336/209/300/300/487
13 5 Gangrenous appendicitis, peritonitis November 37 4/A-B+ 129/404/209/307/307/454
14 10 Pneumonia August 54 1/HA1 276/171/294/365/365/117
15 29 Anterior pituitary hypofunction October 54 1/HA1 218/187/294/414/414/117
16 8 Pneumonia September 103 1/HA1 ND
Isolates causing CDI
17 20 Pancreatitis September 3 1/HA1 292/148/337/351/351/117
18 12 Colon cancer September 37 4/A-B+ 129/367/209/307/307/454
19 19 Liver cirrhosis November 37 4/A-B+ 129/367/209/300/300/420
20 29 Liver cirrhosis September 129 1/HA1 ND
aNames of clades are from reference [9]. bMLVA profile: amplicon size (bp) for loci CDA6, CDG8, CDR5, CDR48, CDR49 and CDR60
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Active screening of elderly patients was therefore able to
identify more carriers of toxigenic C. difficile and was
more resource-efficient than screening all patients. How-
ever, the significance of active screening in clinical
management and infection control needs to be justified
as none of these elderly carriers developed CDI in our
setting. Our findings do not support the active screening
of all patients for toxigenic C. difficile on admission to
ICU, in the setting of a low prevalence of colonization,
to identify patients in high risks of subsequent CDI.
More studies are warranted to confirm whether
colonization with toxigenic C. difficile is truly a high-risk
factor for subsequent CDI in ICU patients.
None of the four patients colonized with a toxigenic
C. difficile had CDI at discharge. A previous study re-
ported that β-lactam-β-lactamase inhibitor combinations
and metronidazole were associated with a loss of C. diffi-
cile colonization [16]. During their ICU stay, three of the
four patients received either piperacillin-tazobactam (n =
2) or cefoperazone-sulbactam (n = 1) and the remaining
patient received metronidazole.
Ten patients had toxigenic C. difficile at discharge and
four patients developed CDI during their ICU stay. The
fourteen patients did not have toxigenic C. difficile on
admission, suggesting that their toxigenic C. difficile
were acquired during their ICU stay. An obvious con-
cern is whether these ICU-acquired isolates were from
those introduced to ICU on admission. However, the
majority (10/14) of ICU-acquired toxigenic C. difficile
belonged to STs, which were not detected on admission.
The remaining four ICU-acquired isolates (2 of ST54, 1
of ST2 and 1 of ST3) matched those detected on admis-
sion with the same ST. However, MLVA analysis revealed
that none of these paired ICU-acquired and introduced
isolates were identical. Therefore, there was no evidence
that the ICU-acquisitions were from those introduced
isolates. This unexpected finding suggests that there were
additional sources (e.g. healthcare workers, visiting family
members or the environment) of toxigenic C. difficile in
ICU, which is yet to be determined. Our findings do not
support the active screening of all patients for toxigenic C.
difficile on admission to ICU in our setting to identify the
potential source of subsequent CDI. In a setting with low
prevalence of colonization, active screening for toxigenic
C. difficile may not be justified as a resource-efficient
measure for the prevention of CDI.
Most of the ICU-acquired toxigenic C. difficile isolates
(8/14) belonged to a single ST, ST37, suggesting possible
transmission of a certain clone in ICU. However, none
of the 8 ST37 isolates were identical by MLVA, which
does not support the hypothesis of the transmission of a
certain clone. Alternatively, although MLVA has been
widely adopted for strain typing and has been success-
fully used for C. difficile [4], it may be too discriminatory
to define clones, which has been observed by other in-
vestigators [17–19]. It is therefore possible that MLVA
may not be an ideal method for investigating the trans-
mission of toxigenic C. difficile. Molecular typing is
critical to track the transmission of toxigenic C. difficile
within hospitals but none of the currently-used typing
methods, including pulsed field gel electrophoresis
(PFGE), restriction enzyme analysis (REA), MLST and
PCR ribotyping, is ideal for C. difficile [20]. Although a
previous study found that MLVA and whole genome se-
quencing had similar discriminatory ability [21], whole
genome sequencing may still be required to untangle
whether there was clonal transmission of toxigenic C.
difficile in ICU.
We found a binary toxin-producing C. difficile isolate,
which colonized (rather than caused CDI) a patient on
admission to ICU. Recent publications showed that
binary toxin is a marker for highly virulent C. difficile or
contributes directly to the virulence [22]. The identifica-
tion of a colonizing binary toxin-positive isolate in this
study highlights that the presence of binary toxin genes
does not necessarily indicate diarrhea, which also de-
pends on host factors.
CDI incidence (10.7 cases per 10,000 ICU days) in this
study was lower than that (25.2 cases per 10,000 ICU
days) of our previous study, which was performed be-
tween May 2012 and January 2013 in the same unit [23].
This could be due to improved infection control prac-
tices in the unit. For instance, hand hygiene compliance
of healthcare workers in the unit had increased from
49.5 % in 2012 to 79.7 % in 2014. Ongoing monitoring
of CDI incidence is required to examine whether the re-
duction of CDI continues.
Our study has several limitations. First, this was a sin-
gle center study and we were not able to collect swabs
from all eligible patients and some additional carriers
might have been missed. Second, this study was carried
out to explore the prevalence of colonization with and
the transmission of toxigenic C. difficile in ICU, we did
not specifically investigate the risk factors for the acqui-
sition of toxigenic C. difficile in ICU. In addition, the
small number of patients colonized with toxigenic C. dif-
ficile may result in our study being underpowered for
the detection of risk factors for colonization. Third, we
did not follow up the carriers who were positive at
discharge from ICU and therefore we were unable to
find out whether these colonizers developed diarrhea
later on. Without follow up we were also unable to deter-
mine whether the colonization of toxigenic C. difficile was
transient or could persist for a period. Fourth, as previous
studies have demonstrated that PCR assays may be less
sensitive than toxigenic culture for detection of asymp-
tomatic carriage of toxigenic C. difficile [12, 13], some car-
riers might have been missed in this study.
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Conclusions
The prevalence of colonization with toxigenic C. difficile
and the incidence of CDI among patients on admission
to ICU were low in our settings. Although some patients
(4.3 %) acquired toxigenic C. difficile and became
asymptomatic carriers during their ICU stay, these ICU-
acquired isolates were not genetically linked with those
carried by patients at admission. Active screening for
toxigenic C. difficile may not be a resource-efficient
measure for the prevention of CDI in such a setting with
a low prevalence of colonization. Importantly, these
conclusions may be not generalizable due to the low
prevalence of C. difficile colonization and CDI in our pa-
tient population.
Abbreviations
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